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OBJECTIVE: Evaluate whether exhaled nitric oxide may serve as a marker of intraoperative bronchospasm. 
INTRODUCTION: Intraoperative bronchospasm remains a challenging event during anesthesia. Previous studies in asthmatic 
patients suggest that exhaled nitric oxide may represent a noninvasive measure of airway inflammation. 
METHODS: A total of 146,358 anesthesia information forms, which were received during the period from 1999 to 2004, were 
reviewed. Bronchospasm was registered on 863 forms. From those, three groups were identified: 9 non-asthmatic patients (Bron-
chospasm group), 12 asthmatics (Asthma group) and 10 subjects with no previous airway disease or symptoms (Control group). 
All subjects were submitted to exhaled nitric oxide measurements (parts/billion), spirometry and the induced sputum test. The data 
was compared by ANOVA followed by the Tukey test and Kruskal-Wallis followed by Dunn’s test.
RESULTS: The normal lung function test results for the Bronchospasm group were different from those of the asthma group (p 
<0.05). The median percentage of eosinophils in induced sputum was higher for the Asthma [2.46 (0.45-6.83)] compared with either 
the Bronchospasm [0.55 (0-1.26)] or the Control group [0.0 (0)] (p <0.05); exhaled nitric oxide followed a similar pattern for the 
Asthma [81.55 (57.6-86.85)], Bronchospasm [46.2 (42.0 -62.6] and Control group [18.7 (16.0-24.7)] (p< 0.05). 
CONCLUSIONS: Non-asthmatic patients with intraoperative bronchospasm detected during anesthesia and endotracheal intuba-
tion showed increased expired nitric oxide. 
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INTRODUCTION
The incidence of perioperative bronchospasm is very 
low, close to 0.17%, but may reach 2.19% among patients 
with obstructive disease.1 Up to 45% of asthmatic patients 
present wheezing during anesthetic induction, while 16% of 
non-asthmatic patients show the same event.2
Anesthetists should be aware of the precipitating factors, 
recognize the signs and be prepared to undertake a logical 
plan for management of perioperative bronchospasm. In 
patients with bronchial hyperreactivity, airway instrumentation 
may evoke life-threatening bronchospasm, perioperative 
complications, and prolonged intensive care treatment.2,3 
Despite major advances in our understanding of the 
clinical management of intraoperative bronchospasm, 
it remains a challenging situation for anesthesiologists 
in clinical practice. Airways of patients with bronchial 
hyperreactivity  are  characterized  by  exaggerated 
bronchoconstriction in response to a variety of stimuli.4
Nitric oxide (NO) of endogenous origin is present in 
exhaled breath.5 NO participates in the physiologic regulation 
of bronchomotor tonus, but is also involved in diseases, such 
as asthma.6 An increase in the concentration of exhaled NO 
(ENO) has been described with bronchial asthma.7,8 Previous 
studies have raised the possibility that the measurement of 
NO concentrations in expired air may represent a noninvasive 
measure of lower airway inflammation.9,10 The aim of this 
investigation was to address the possibility of using exhaled 
NO as a marker of intraoperative bronchospasm.6
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METHODS AND MATERIALS
The present investigation was approved by the Research 
Ethics Committee of the University of São Paulo Medical 
School and informed written consent was obtained from 
patients (ClinicalTrials.gov protocol NCT00666510). In 
order to find eligible patients, the first step was to identify 
patients with registered intraoperative bronchospasm during 
tracheal intubation. The identified patients had written 
statements of intraoperative bronchospasm in their registered 
anesthesia forms and received subsequent measures to 
overcome that adverse event. These measures generally 
included administration of a bronchodilator via a nebulizer 
inside the tracheal tube or intravenously. By review of 
146,358 anesthetic-surgical case forms recorded by the 
Anesthesiology Division from 1999 to 2004 (Figure 1), those 
with registered bronchospasm were identified. From these 
records, we did not include those who met the exclusion 
criteria (severe systemic disease, liver transplantation, 
Chronic Obstrutive Pulmonary Disease – COPD, auto-
immune disease, corticoid therapy, cancer, elderly (above 
60 years) or young (below 16 years), pregnancy, smoking 
history at the time of surgery and identified asthma), which 
may affect the ENO measurement. Eligible patients were 
invited by phone to return to the hospital for a clinical 
assessment. After the interview and clinical exam, the 
patients, all of whom underwent bronchospasm during 
intubation, were further classified into two groups, non-
asthmatics (9 subjects) and asthmatics (12 patients). 
Importantly, none of the asthmatic patients had a clinical 
diagnosis of asthma before this clinical assessment or as of 
the chosen anesthetic procedure. In addition, a third group of 
10 subjects, who had undergone a surgical procedure under 
general anesthesia without any sign of respiratory adverse 
events or any history of intraoperative bronchospasm, was 
selected as a control group. These subjects were enlisted 
from the case forms that were described previously.
Patients were seen for clinical examination on two visits 
within one month. During the first visit, exhaled air was 
collected for the measurement of ENO with spirometry, 
which was the primary endpoint of the study. In addition, 
induced sputum was collected and blood was collected, 
which was then submitted to an IgE measurement. Additional 
laboratory tests were performed to exclude other systemic 
diseases. During the second visit, each of the subjects was 
submitted to a routine follow-up examination, skin allergy 
prick tests and chest radiographs (Figure 1). In addition, 
spirometry was performed on all subjects according to the 
guidelines put forth by the American Thoracic Society (ATS) 
and using the ATS standardization for the Koko Spirometer 
(POS Instrumentation, Inc., Louisville, CO, USA).11,12
Participants also completed a medical questionnaire 
about asthma medications, concomitant illnesses (including 
allergies), history of cigarette smoking and events that 
triggered the current asthma. None of the subjects were 
found to have or have had any of the following: heart 
disease, diabetes, hypertension, renal insufficiency, elevated 
serum creatinine concentrations, stroke, altered EKG, COPD, 
cancer, emergency surgery or current pregnancy. 
The asthmatic patients were studied during a clinically 
stable period. The subject characteristics are summarized 
in Table 1. ENO was collected offline and the evaluation 
was made before spirometry. They were required to inhale 
orally through a mouthpiece containing a 0.3 µm bacterial 
HEPA filter (TROX Technik Ltda, SP, Brazil)8 attached to 
the sampling kit (Sievers Instruments Inc., Boulder, CO, 
USA).
Following international recommendations, this kit 
contains a pressure gauge and an inspiratory filter that 
washes out the NO concentration from the inhaled air. In 
order to avoid a sample from dead space gas, the subject was 
instructed to breathe through the sampling kit for a minimum 
of two breaths to ensure tidal volumes and to use a nose clip 
to avoid nasal contamination.13,14 During the next expiration, 
the volunteer had to produce a breath pressure of 12 cm 
H20, which was indicated by a pressure gauge reported flow 
rate of 200 mL.s-1 when pushed into a stainless steel valve 
on the sampling kit after 3 seconds of exhalation, avoiding 
Figure 1 - Study design7
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the dead space gas, and continued for about 2 seconds for 
a collected volume larger than 50 mL (each sample).14 The 
breath sample was collected in an NO impermeable reservoir 
bag (Mylar bag; Sievers Instruments Inc. Boulder, CO, 
USA) with a volume capacity of 1.5 L. The subject repeated 
the procedure until three bags were filled. These bags were 
sealed and immediately analyzed for the concentration of 
ENO by chemiluminescence (Sievers model NOA 280, 
Boulder, CO, USA).8,13 The variability among measured NO 
concentrations was less than 10% and the recorded result 
was the average of the ENO values for the three bags.
Pulmonary function tests were performed for all 
subjects using an ATS standardized Koko Spirometer (POS 
Instrumentation, Inc., Louisville, CO).11,12 Spirometry was 
performed before and after beta-2 agonist inhalation. After 
the spirometric measurement, the sputum was induced 
with 3% hypertonic saline concentrations in an aerosol 
formulation from an ultrasonic nebulizer.15
Sputum samples were visually separated from saliva 
with the help of an inverted microscope and divided into 
two aliquots. One part was spread over a glass slide prior 
to fixation and staining with Diff Quick (Sigma-Aldrich, 
SP, Brazil).16 The second aliquot was treated with 0.1% 
dithiothreitol (Sigma-Aldrich, SP, Brazil) and submitted 
to a total cell count with a hemocytometer (Neubauer 
chamber).17
In vitro tests for the quantitative determination of IgE in 
human serum and skin tests to detect fungi, pollen, mites, 
cat, dog, and cockroach allergies were performed according 
to routine laboratory and standard procedures.18,19
Statistical analysis
Data are presented as means and standard deviations 
(SD) or medians and 25th and 75th percentiles. To evaluate 
ENO values, cytological data and IgE titers, Kruskal–Wallis 
non-parametric analysis of variance followed by Dunn’s test 
were used. To compare spirometry data, analysis of variance 
followed by the Tukey test was used. A p value lower than 
0.05 was considered significant.
RESULTS
A total of 863 documented intraoperative bronchospasms 
with relevant histories were identified among the 146,358 
forms that were obtained during the study period. Of these, 
277 were excluded due to liver transplantation, COPD, auto-
immune disease, corticoid therapy, and cancer. In addition, 
we excluded 175 older patients (> 60 years old), 139 children 
(age ≤16 yr) and 39 smokers. Finally, 160 patients with 
bronchospasms that could not be reached by phone or regular 
mail were excluded. Thus, of the remaining 73 patients, 52 
patients with a documented history of asthma and 21 patients 
who were supposedly non-asthmatic but had a history of 
bronchospasm were selected as the study group.
After selection of study patients based on their anesthesia 
records, those with an established diagnosis of asthma were 
asked to come in for clinical examination. Of the 52 who had 
an established asthmatic condition, 13 were reached by phone; 
of the 13, 12 accepted and 1 declared that she was pregnant 
and was thus ineligible. Of the 21 non-asthmatic patients with 
a history of bronchospasm under intraoperative anesthesia, 
we were able to contact 18 subjects. Of the 18, 6 refused 
to participate, 1 could not perform the pulmonary function 
test correctly, resulting in test errors, and 2 were diagnosed 
with mild COPD from the first medical examination; in 
total, these 9 patients were excluded from the study. The 
remaining 9 patients had shown no signs and no history of 
any respiratory disease after the first medical examination and 
were considered as being free of pulmonary disease. 
A control group was selected from healthy volunteers 
with no adverse events reported in the anesthesia records 
(Table 2, Figure 1). 
The anesthetics used for the study patients were: propofol 
(1.5 to 2.5 mg.kg-1) alone or in association with midazolam 
(0.1 mg.kg-1), fentanyl (5 to 10 mcg.kg-1) or alfentanyl (10 
to 20 mcg.kg-1) and rocuronium (0.6 mg.kg-1) during the 
induction of anesthesia. There was no record of difficult 
intubation or insufficient anesthetic infusion resulting in 
inadequate anesthesia depth among subjects in the observed 
group. For maintenance, all patients received isoflurane or 
sevoflurane.
Table 1 - Subject characteristics
Group Control 
(n=10)
Bronchospasm 
(n=9)
Asthma 
(n=12)
Age Range, 
yr,Mean±SD
(39-51) 
41.90±3.54
(17-60) 
37.22±15.37
(19-53) 
30.33±11.04
Sex
    Female 
    Male
8 
2
6 
3
8 
4
Current smoker 0 1 1
Past smoker 2 0 2
History of rhinitis 0 0 10
History of 
dermatitis
0 1 1
History of 
sinusitis
0 0 7
β2-agonist or 
corticosteroids
0 0 12
Gastroesophageal 
reflux disease
0 0 2
Data from medical questionnaire. Age is presented as mean±SD. 8
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ENO was higher in the asthmatic patients than in the 
control patients (p=0.001), but the levels in asthmatic patients 
were similar to those in the group with bronchospasm 
(Table 2, Figure 2). The bronchospasm group’s ENO was 
significantly different from the ENO for the control group 
(p=0.005). Pulmonary function test results showed that the 
asthma group was significantly different from the control 
group. The bronchospasm group had a normal spirometry 
test and no differences were observed compared with the 
control group for this test (Table 3). 
The percentage of eosinophils in the sputum was 
significantly different between the asthmatics and controls 
(Table 2). The eosinophil percentage from the bronchospasm 
group did not differ significantly from that of the asthmatics; 
the median was very near zero, close to that for the control 
group. All patients showed slightly elevated neutrophil levels, 
but asthmatics had higher concentrations that the other groups. 
The total cell counts did not show any differences by group 
(Table 2). 
Table 2 - Inflammatory markers (median [25%-75%])
Group Control Median 
[25%-75%]
Bronchospasm Median 
[25%-75%]
Asthma Median 
[25%-75%]
P 
CTC/mL.106 IS 0.36 [0.26-0.90] 1.30 [0.23-2.60] 1.08 [0.61-2.00] NS
EOS (%) IS 0 [0 – 0] 0.55 [0-1.26] 2.46 [0.45-6.83*] *0.002
Neu (%) IS 40.45 [24.40-57.00] 55.20 [21.89-63.92] 63.78 [25.06-78.10]  NS
IgE UL/mL Serum 35.50 [14.00- 61.00] 110.00 [67.47-395.50] 523.00 [193.00-1220.00*] *0.001
ENO (ppb)  18.70 [16.00-24.70] 46.20 [42.00-62.60**] 81.55 [57.60-86.85*] * 0.001
** 0.005
CTC/mL.106 IS, total cell count in the induced sputum; EOS (%) IS, percentage of eosinophils; Neu (%) IS, percentage of neutrophils; IgE UI.ml-1 Serum, 
immunoglobulin E in the serum; ENO (ppb), exhaled nitric oxide. *Asthma compared with Control; **Bronchospam compared with Control; NS, Non 
Significant.
Figure 2 - Exhaled nitric oxide parts per billion (ENO ppb) measurements 
from healthy subjects (control) and subjects with history of bronchospasm 
in intraoperative period (Bronchospasm and Asthma). The boxplot shows 
the 25th, 50th and 75th percentiles, with the extreme bars representing the 10th 
and 90th percentiles. ENO (ppb) measure, *p = 0.001 compared with control 
and **p = 0.005 compared with control.
Table 3 - Spirometric data 
Group Control Mean±SD Bronchospasm Mean±SD Asthma Mean±SD P
FVCpred(%) 107.90±13.94 98.78±6.85 94.58±20.83 NS
FVCafter(%) 105.90±12.90 98.67±7.94 97.92±19.41 NS
FEV1pred (%) 108.80±11.99 99.44±9.79 83.83±18.48*† *0.0003 
†0.020
FEV1after (%) 109.30±12.39 103.22±8.42 91.00±19.59 NS
FEV1/FVCpred (%) 101.40±6.10 101.89±6.15 89.00±11.65*† †*0.002
FEV1/FVCafter (%) 103.20±4.52 105.44±4.33 93.83±12.50† †0.005
FEF25-75pred (%) 104.00±24.79 95.78±27.64 61.83±24.79*† *0.001 
†0.01
FEF25-75 after (%) 112.50±21.78 107.89±28.07 74.50±30.49*† *0.003 
†0.001
FVC - Forced vital capacity; FEV1 - Forced expiratory volume in 1s; FEV1/FVC; relation between FEV1 and FVC; FEF25%-75% - Forced expiratory flow 
between 25%-75% of vital capacity: Pred - expected for age and height and After- after β2-agonist. * Compared with Control Group; † Compared with 
Bronchospasm; NS Non Significant.9
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The serum IgE levels were greater for the asthma group 
(523.00 [193.00-1220.00]) compared with those for the 
control group (35.50 [14.00- 61.00]), but they were not 
different from the levels in the bronchospasm group (110.00 
[67.47-395.50]); again, the asthmatics differed from the 
control group but not from the bronchospasm group (Table 
2). The prick test showed a variety of positive results with 
slightly higher positivity among asthmatics.
DISCUSSION
Asthma is a serious and widespread epidemiological 
problem, with a relatively high level of prevalence in the 
city of São Paulo.20 This study showed high ENO levels in 
patients with registered bronchospasm induced by tracheal 
intubation during anesthesia but no history of asthma disease. 
This result supports the notion that NO is associated with 
airway hyperresponsiveness, although it raises the question 
of whether it also reflects airway inflammation.
Several studies have shown that NO is an inflammatory 
marker  as  well  as  a  surrogate  measure  of  airway 
inflammation in patients with asthma.21-23 In this study, we 
observed elevated NO concentrations in the bronchospasm 
group, which was comprised of patients with no previous 
history of airway inflammation. It has been shown that 
measurements of ENO may represent a noninvasive approach 
for assessing the degree of current airway inflammation.24-26 
However, some studies did not find a correlation between 
ENO and bronchial hyperresponsiveness.16,27 NO is 
considered an important mediator of countless physiological 
processes in the respiratory system as well as a factor that is 
involved in the pathophysiology of asthma.25 Thus, it seems 
reasonable to consider NO as a potential marker of airway 
hyperresponsiveness as well as airway inflammation.
Despite the bronchospasm group showing a wide age 
range, studies do not show a consistent relationship between 
NO and age for adults.28 In this subsample of patients, 
serum IgE and induced sputum cells were slightly elevated, 
although in the normal range. Also, the spirometry data did 
not show lower values for this subgroup. It is interesting 
to note that these normal results precluded the diagnosis 
of asthma, but the elevated NO levels observed in the 
bronchospasm group indicates that they had hyperresponsive 
airways. 
Induced  sputum  is  a  reliable  test  that  enables 
differentiation of healthy airways from asthmatic airways, 
for which eosinophils are considered an important marker.17 
Some studies have shown that induced sputum is a useful 
and safe evaluation method for the detection of asthma 
and airway inflammation.29-31 Our patients that were found 
to have high NO concentrations did not show eosinophil 
results that were compatible with an inflammatory airway, 
since inflammatory cells were not present in their induced 
sputum.
In a previous report, baseline airway hyperresponsiveness 
was related to FEV1 (Forced Expiratory Volume in the first 
second) but not to inflammatory parameters, such as ENO.32 
By contrast, in our study, healthy patients with bronchospasm 
presented normal spirometry but had bronchospasms and 
higher ENO levels. Whether ENO could be considered a 
useful method to predict bronchial hyperresponsiveness for 
nonasthmatic patients remains to be shown.33,34 Although the 
anesthesiologist may deal with such an unexpected event 
pharmacologically, these patients may represent an at-risk 
population.
It is important to note that a standardized bronchial 
provocation PC20 would have greatly enriched our 
study. However, we thought that this test would expose 
patients to unnecessary risk, particularly the patients with 
bronchospasm who showed elevated NO values, which 
is suggestive of airway hyperreactivity. The absence of 
this test certainly impaired the sensitivity of our protocol, 
but we decided against using this test for patient safety. 
Nevertheless, it would be reasonable to consider ENO as an 
associated marker for hyperresponsiveness that is similar to 
bronchoprovocation, but with lower risks.35-37 In addition, 
some authors have suggested that hyperresponsiveness may 
not be related to airway tissue inflammation.38,39
In conclusion, the ENO concentrations were higher 
among  non-asthmatic  patients  with  intraoperative 
bronchospasm associated with endotracheal intubation. 
Although this report suggests a clinical role for monitoring 
ENO concentrations, the results should be interpreted with 
caution due to the cross-sectional nature of this study. 
A prospective longitudinal study is required in order to 
establish predictive correlations.
This work was supported by the following Brazilian 
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